Cargando…

PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients

Myeloproliferative neoplasms (MPNs) are characterized by upregulation of proinflammatory cytokines and immune dysregulation, which provide a reasonable basis for immunotherapy in patients. Megakaryocytes are crucial in the pathogenesis of primary myelofibrosis (PMF), the most clinically aggressive s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sze‐Hwei, Lin, Chien‐Chin, Wei, Chao‐Hong, Chang, Ko‐Ping, Yuan, Chang‐Tsu, Tsai, Cheng‐Hong, Liu, Jia‐Hao, Hou, Hsin‐An, Tang, Jih‐Lu, Chou, Wen‐Chien, Tien, Hwei‐Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682945/
https://www.ncbi.nlm.nih.gov/pubmed/34480529
http://dx.doi.org/10.1002/cjp2.240
_version_ 1784617314888450048
author Lee, Sze‐Hwei
Lin, Chien‐Chin
Wei, Chao‐Hong
Chang, Ko‐Ping
Yuan, Chang‐Tsu
Tsai, Cheng‐Hong
Liu, Jia‐Hao
Hou, Hsin‐An
Tang, Jih‐Lu
Chou, Wen‐Chien
Tien, Hwei‐Fang
author_facet Lee, Sze‐Hwei
Lin, Chien‐Chin
Wei, Chao‐Hong
Chang, Ko‐Ping
Yuan, Chang‐Tsu
Tsai, Cheng‐Hong
Liu, Jia‐Hao
Hou, Hsin‐An
Tang, Jih‐Lu
Chou, Wen‐Chien
Tien, Hwei‐Fang
author_sort Lee, Sze‐Hwei
collection PubMed
description Myeloproliferative neoplasms (MPNs) are characterized by upregulation of proinflammatory cytokines and immune dysregulation, which provide a reasonable basis for immunotherapy in patients. Megakaryocytes are crucial in the pathogenesis of primary myelofibrosis (PMF), the most clinically aggressive subtype of MPN. In this study, we aimed to explore PD‐L1 (programmed death‐ligand 1) expression in megakaryocytes and its clinical implications in PMF. We analyzed PD‐L1 expression on megakaryocytes in PMF patients by immunohistochemistry and correlated the results with clinicopathological features and molecular aberrations. We employed a two‐tier grading system considering both the proportion of cells positively stained and the intensity of staining. Among the 85 PMF patients, 41 (48%) showed positive PD‐L1 expression on megakaryocytes with the immune‐reactive score ranging from 1 to 12. PD‐L1 expression correlated closely with higher white blood cell count (p = 0.045), overt myelofibrosis (p = 0.010), JAK2V617F mutation (p = 0.011), and high‐molecular risk mutations (p = 0.045), leading to less favorable overall survival in these patients (hazard ratio 0.341, 95% CI 0.135–0.863, p = 0.023). Our study provides unique insights into the interaction between immunologic and molecular phenotypes in PMF patients. Future work to explore the translational potential of PD‐L1 in the clinical setting is needed.
format Online
Article
Text
id pubmed-8682945
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-86829452021-12-30 PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients Lee, Sze‐Hwei Lin, Chien‐Chin Wei, Chao‐Hong Chang, Ko‐Ping Yuan, Chang‐Tsu Tsai, Cheng‐Hong Liu, Jia‐Hao Hou, Hsin‐An Tang, Jih‐Lu Chou, Wen‐Chien Tien, Hwei‐Fang J Pathol Clin Res Original Articles Myeloproliferative neoplasms (MPNs) are characterized by upregulation of proinflammatory cytokines and immune dysregulation, which provide a reasonable basis for immunotherapy in patients. Megakaryocytes are crucial in the pathogenesis of primary myelofibrosis (PMF), the most clinically aggressive subtype of MPN. In this study, we aimed to explore PD‐L1 (programmed death‐ligand 1) expression in megakaryocytes and its clinical implications in PMF. We analyzed PD‐L1 expression on megakaryocytes in PMF patients by immunohistochemistry and correlated the results with clinicopathological features and molecular aberrations. We employed a two‐tier grading system considering both the proportion of cells positively stained and the intensity of staining. Among the 85 PMF patients, 41 (48%) showed positive PD‐L1 expression on megakaryocytes with the immune‐reactive score ranging from 1 to 12. PD‐L1 expression correlated closely with higher white blood cell count (p = 0.045), overt myelofibrosis (p = 0.010), JAK2V617F mutation (p = 0.011), and high‐molecular risk mutations (p = 0.045), leading to less favorable overall survival in these patients (hazard ratio 0.341, 95% CI 0.135–0.863, p = 0.023). Our study provides unique insights into the interaction between immunologic and molecular phenotypes in PMF patients. Future work to explore the translational potential of PD‐L1 in the clinical setting is needed. John Wiley & Sons, Inc. 2021-09-04 /pmc/articles/PMC8682945/ /pubmed/34480529 http://dx.doi.org/10.1002/cjp2.240 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Lee, Sze‐Hwei
Lin, Chien‐Chin
Wei, Chao‐Hong
Chang, Ko‐Ping
Yuan, Chang‐Tsu
Tsai, Cheng‐Hong
Liu, Jia‐Hao
Hou, Hsin‐An
Tang, Jih‐Lu
Chou, Wen‐Chien
Tien, Hwei‐Fang
PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
title PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
title_full PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
title_fullStr PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
title_full_unstemmed PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
title_short PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
title_sort pd‐l1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8682945/
https://www.ncbi.nlm.nih.gov/pubmed/34480529
http://dx.doi.org/10.1002/cjp2.240
work_keys_str_mv AT leeszehwei pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT linchienchin pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT weichaohong pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT changkoping pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT yuanchangtsu pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT tsaichenghong pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT liujiahao pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT houhsinan pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT tangjihlu pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT chouwenchien pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients
AT tienhweifang pdl1expressioninmegakaryocytesanditsclinicopathologicalfeaturesinprimarymyelofibrosispatients